References
- Fuchs M, Goergen H, Kobe C, et al. Positron emission tomography-guided treatment in early-stage favorable hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the german hodgkin study group. J Clin Oncol. 2019 Nov 1;37(31):2835–2845.
- Bjork-Eriksson T, Bjelkengren G, Glimelius B. The potentials of proton beam radiation therapy in malignant lymphoma, thymoma and sarcoma. Acta Oncol. 2005;44(8):913–917.
- Chera BS, Rodriguez C, Morris CG, et al. Dosimetric comparison of three different involved nodal irradiation techniques for stage II hodgkin’s lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1173–1180.
- Hoppe BS, Flampouri S, Su Z, et al. Consolidative involved-node proton therapy for stage IA-IIIB mediastinal hodgkin lymphoma: preliminary dosimetric outcomes from a phase II study. Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):260–267.
- Maraldo MV, Brodin NP, Aznar MC, et al. Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal hodgkin lymphoma. Ann Oncol. 2013 Aug;24(8):2113–2118.
- Cella L, Conson M, Pressello MC, et al. Hodgkin’s lymphoma emerging radiation treatment techniques: trade-offs between late radio-induced toxicities and secondary malignant neoplasms. Radiat Oncol. 2013 Jan 30;8:22.
- Tseng YD, Cutter DJ, Plastaras JP, et al. Evidence-based review on the use of proton therapy in lymphoma from the Particle Therapy Cooperative Group (PTCOG) lymphoma subcommittee. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):825–842.
- van Nimwegen FA, Ntentas G, Darby SC, et al. Risk of heart failure in survivors of hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines. Blood. 2017 Apr 20;129(16):2257–2265.
- van Nimwegen FA, Schaapveld M, Cutter DJ, et al. Radiation dose-response relationship for risk of coronary heart disease in survivors of hodgkin lymphoma. J Clin Oncol. 2016 Jan 20;34(3):235–243.
- Hoppe BS, Hill-Kayser CE, Tseng YD, et al. Consolidative proton therapy after chemotherapy for patients with hodgkin lymphoma. Ann Oncol. 2017 Sep 1;28(9):2179–2184.
- Nanda R, Flampouri S, Mendenhall NP, et al. Pulmonary toxicity following proton therapy for thoracic lymphoma. Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):494–497.
- Pinnix CC, Huo J, Milgrom SA, et al. Using benchmarked lung radiation dose constraints to predict pneumonitis risk: developing a nomogram for patients with mediastinal lymphoma. Adv Radiat Oncol. 2018 Jul-Sep;3(3):372–381.
- Dabaja BS, Hoppe BS, Plastaras JP, et al. Proton therapy for adults with mediastinal lymphomas: the international lymphoma radiation oncology group guidelines. Blood. 2018 Oct 18;132(16):1635–1646.
- Hoppe BS, Bates JE, Mendenhall NP, et al. The meaningless meaning of mean heart dose in mediastinal lymphoma in the modern radiotherapy era. Pract Radiat Oncol. 2019 Oct 2. pii: S1879-8500(19)30279-6.
- Cutter DJ, Schaapveld M, Darby SC, et al. Risk of valvular heart disease after treatment for hodgkin lymphoma. J Natl Cancer Inst. 2015 Apr;107(4). doi: 10.1093/jnci/djv008
- Hoppe BS, Flampouri S, Su Z, et al. Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2012 Oct 1;84(2):449–455.
- Guzhva L, Mendenhall NP, Morris CG, et al. Evaluating cardiac biomarkers after chemotherapy and proton therapy for mediastinal hodgkin lymphoma. Int J Part Ther. 2017;4(2):35–38.
- Demissei BG, Freedman G, Feigenberg SJ, et al. Early changes in cardiovascular biomarkers with contemporary thoracic radiation therapy for breast cancer, lung cancer, and lymphoma. Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):851–860.
- Bates JE, Howell RM, Liu Q, et al. Therapy-related cardiac risk in childhood cancer survivors: an analysis of the childhood cancer survivor study. J Clin Oncol. 2019 May 1;37(13):1090–1101.
- Turcotte LM, Liu Q, Yasui Y, et al. Temporal trends in treatment and subsequent neoplasm risk among 5-year survivors of childhood cancer, 1970–2015. JAMA. 2017 Feb 28;317(8):814–824.
- Sachsman S, Flampouri S, Li Z, et al. Proton therapy in the management of non-hodgkin lymphoma. Leuk Lymphoma. 2015;56(9):2608–2612.
- Figura NB, Flampouri S, Hopper K, et al. Consolidative proton therapy following high-dose chemotherapy and autologous stem cell transplant in an adolescent with relapsed hodgkin lymphoma. J Adolesc Young Adult Oncol. 2011 Jun;1(2):103–106.